Index RUT
P/E -
EPS (ttm) -0.91
Insider Own 14.36%
Shs Outstand 35.17M
Perf Week -1.10%
Market Cap 635.78M
Forward P/E 29.78
EPS next Y 0.60
Insider Trans 3.65%
Shs Float 30.30M
Perf Month 12.84%
Income -31.33M
PEG -
EPS next Q -0.18
Inst Own 58.21%
Short Float 14.14%
Perf Quarter 71.31%
Sales 138.68M
P/S 4.58
EPS this Y 28.33%
Inst Trans -4.54%
Short Ratio 8.01
Perf Half Y 78.98%
Book/sh 1.70
P/B 10.58
EPS next Y 212.25%
ROA -12.23%
Short Interest 4.28M
Perf Year -7.85%
Cash/sh 2.15
P/C 8.37
EPS next 5Y 15.00%
ROE -76.44%
52W Range 7.60 - 22.63
Perf YTD 60.45%
Dividend Est. -
P/FCF 99.81
EPS past 5Y -
ROI -12.49%
52W High -20.59%
Beta 0.75
Dividend TTM -
Quick Ratio 2.73
Sales past 5Y 27.34%
Gross Margin 69.77%
52W Low 136.45%
ATR (14) 0.95
Dividend Ex-Date -
Current Ratio 2.99
EPS Y/Y TTM -40.50%
Oper. Margin -5.28%
RSI (14) 64.56
Volatility 5.35% 5.33%
Employees 315
Debt/Eq 3.19
Sales Y/Y TTM 49.79%
Profit Margin -22.59%
Recom 1.00
Target Price 28.15
Option/Short Yes / Yes
LT Debt/Eq 3.18
EPS Q/Q -74.37%
Payout -
Rel Volume 0.74
Prev Close 17.94
Sales Surprise -4.77%
EPS Surprise -74.71%
Sales Q/Q 32.50%
Earnings May 13 AMC
Avg Volume 534.93K
Price 17.97
SMA20 2.25%
SMA50 27.81%
SMA200 44.79%
Trades
Volume 397,647
Change 0.17%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-11-24 Initiated
Craig Hallum
Buy
$24
Sep-08-22 Resumed
B. Riley Securities
Buy
$17
Oct-14-21 Resumed
B. Riley Securities
Buy
$16
Sep-24-21 Initiated
Aegis Capital
Buy
$15
Jul-02-21 Initiated
Ladenburg Thalmann
Buy
$14.25
Jun-07-24 06:30AM
Jun-06-24 08:00AM
Jun-05-24 07:00AM
May-15-24 07:00AM
May-13-24 08:55PM
04:25PM
Loading…
04:25PM
04:01PM
07:00AM
Apr-25-24 07:00AM
Apr-02-24 08:16AM
Mar-21-24 09:55AM
Mar-19-24 09:52PM
06:51PM
05:45PM
Mar-13-24 06:35AM
07:00AM
Loading…
Mar-05-24 07:00AM
Mar-04-24 08:28PM
Feb-21-24 06:47AM
Feb-15-24 04:01PM
Jan-29-24 07:00AM
Jan-11-24 07:00AM
Jan-03-24 07:15AM
07:00AM
Dec-24-23 01:08PM
Nov-29-23 07:00AM
Nov-20-23 07:00AM
Nov-14-23 12:56PM
Nov-13-23 05:07PM
04:01PM
Oct-30-23 08:00AM
07:00AM
Loading…
Oct-24-23 07:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-21-23 01:03PM
Aug-11-23 01:05PM
Aug-10-23 09:54AM
(Thomson Reuters StreetEvents) -15.45%
Aug-09-23 04:14PM
(Associated Press Finance)
04:01PM
Jul-31-23 07:00AM
Jul-28-23 02:56PM
Jul-26-23 03:42PM
(American City Business Journals)
09:00AM
Jul-20-23 10:29AM
Jul-19-23 12:17PM
07:00AM
Jul-18-23 05:00PM
04:05PM
04:04PM
04:01PM
Jul-05-23 06:15PM
Jun-29-23 06:15PM
Jun-23-23 06:15PM
Jun-16-23 06:00PM
May-17-23 08:00AM
May-16-23 11:57AM
May-15-23 11:21AM
May-12-23 01:48PM
06:26AM
(Thomson Reuters StreetEvents)
May-11-23 05:15PM
04:29PM
04:01PM
May-08-23 12:07PM
May-04-23 08:00AM
04:59AM
May-03-23 06:44AM
May-02-23 04:42PM
09:40AM
07:00AM
May-01-23 08:50AM
Apr-28-23 06:00PM
05:00AM
Apr-27-23 08:05AM
08:00AM
Apr-24-23 08:43AM
07:09AM
Apr-20-23 08:31AM
Apr-19-23 06:15PM
08:31AM
Apr-18-23 06:24AM
Apr-14-23 08:50AM
Apr-13-23 06:15PM
Apr-12-23 09:40AM
Apr-09-23 04:04PM
(The Wall Street Journal)
Apr-05-23 09:34AM
Apr-04-23 05:37AM
Apr-03-23 06:53AM
Mar-29-23 08:50AM
Mar-28-23 02:59PM
07:00AM
Mar-27-23 08:51AM
Mar-24-23 05:42AM
(Thomson Reuters StreetEvents) +6.78%
Mar-23-23 04:06PM
Mar-13-23 07:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-16-23 06:42AM
Feb-15-23 07:00AM
Feb-03-23 08:50AM
Feb-02-23 06:30AM
Jan-23-23 07:00AM
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Opaleye Management Inc. 10% Owner Apr 25 '24 Buy 9.97 20,000 199,400 3,815,000 Apr 25 05:19 PM Opaleye Management Inc. 10% Owner Apr 24 '24 Buy 10.15 8,285 84,093 3,795,000 Apr 24 04:40 PM Opaleye Management Inc. 10% Owner Apr 23 '24 Buy 10.29 11,715 120,547 3,786,715 Apr 24 04:40 PM Opaleye Management Inc. 10% Owner Apr 19 '24 Buy 10.56 29,400 310,390 3,775,000 Apr 19 06:24 PM Opaleye Management Inc. 10% Owner Mar 28 '24 Buy 12.82 50,000 641,000 3,745,600 Mar 28 06:07 PM BAUM MARK L CHIEF EXECUTIVE OFFICER Mar 22 '24 Buy 11.59 9,000 104,310 2,137,525 Mar 25 07:00 AM Opaleye Management Inc. 10% Owner Mar 20 '24 Buy 9.65 50,600 488,290 3,695,600 Mar 22 11:52 AM SAHAREK JOHN P. CEO of ImprimisRx Mar 01 '24 Option Exercise 8.75 5,000 43,750 254,803 Mar 06 06:06 AM BAUM MARK L CHIEF EXECUTIVE OFFICER Feb 20 '24 Option Exercise 10.67 150,000 1,600,500 2,188,361 Feb 21 07:29 PM BOLL ANDREW R. CHIEF FINANCIAL OFFICER Feb 20 '24 Option Exercise 10.67 45,000 480,150 586,569 Feb 21 07:29 PM SAHAREK JOHN P. CEO of ImprimisRx Feb 20 '24 Option Exercise 10.67 30,000 320,100 262,419 Feb 21 07:30 PM BAUM MARK L CHIEF EXECUTIVE OFFICER Feb 07 '24 Option Exercise 7.71 15,400 118,734 2,038,361 Feb 08 07:30 AM BOLL ANDREW R. CHIEF FINANCIAL OFFICER Feb 07 '24 Option Exercise 7.71 7,400 57,054 541,569 Feb 08 07:30 AM BAUM MARK L Chief Executive Officer Nov 16 '23 Buy 8.11 7,500 60,825 2,022,961 Nov 16 04:45 PM Opaleye Management Inc. 10% Owner Nov 15 '23 Buy 8.03 25,000 200,735 3,645,000 Nov 16 04:05 PM Opaleye Management Inc. 10% Owner Sep 20 '23 Buy 14.49 5,983 86,710 3,620,000 Sep 20 06:39 PM Opaleye Management Inc. 10% Owner Sep 19 '23 Buy 14.65 14,017 205,366 3,614,017 Sep 20 06:39 PM Makary Martin A. Director Aug 14 '23 Buy 16.92 20,000 338,400 45,000 Aug 15 07:30 AM BAUM MARK L Chief Executive Officer Aug 14 '23 Buy 17.05 5,800 98,890 2,015,461 Aug 15 07:30 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite